Likes ReceivedThe Traditional Chinese Medicine ETF (560080) by China Universal Asset Management has fallen to its recent low, with frequent intraday premium occurrences.
On April 22, the market edged up slightly, while the Traditional Chinese Medicine (TCM) sector fluctuated and declined. As of 14:31, the TCM ETF Huatai-PineBridge (560080) fell by 0.40%, with turnover exceeding 59 million yuan, and intraday premiums frequently appeared. Among the constituent stocks, Pien Tze Huang fell nearly 2% to hit a new low for the period, Yunnan Baiyao and Dong-E-E-Jiao fell over 1%, while JiuZhiTang rose over 4%, and ZuoLi Pharmaceutical, GuangYuYuan, and KangYuan Pharmaceutical rose over 2%.
While the sector is adjusting, capital continues to pour in. Authoritative data from the Shanghai Stock Exchange shows that the TCM ETF Huatai-PineBridge (560080) has seen net capital inflows for four consecutive days, totaling over 57 million yuan!
Data shows that the latest size of the TCM ETF Huatai-PineBridge (560080) has reached 2.542 billion yuan, ranking first among ETFs tracking the same underlying index, with a fund size exceeding 2.5 billion yuan!
The TCM industry is welcoming multiple heavyweight policies, with the core aim of "expanding market boundaries and raising quality thresholds," pushing the industry from fragmented competition towards refined value competition.
On April 14, relevant authorities issued the "Several Opinions on Improving the Drug Price Formation Mechanism," emphasizing the decisive role of the market in resource allocation, better leveraging the role of the government, and effectively serving the construction of a national unified market in the pharmaceutical field.
On the 16th, the "Hospital Traditional Chinese Medicine Decoction Pieces Management Standard (2026 Edition)" was issued, further standardizing the management of TCM decoction pieces in hospitals, ensuring the safety and effectiveness of human medication, and enhancing the disease prevention, treatment capabilities, and clinical efficacy of TCM.
Furthermore, the newly revised "Regulations for the Implementation of the Drug Administration Law" will officially take effect from May 15. The "Regulations" clarify that TCM decoction pieces processed according to the processing standards formulated by provincial drug regulatory departments can be sold and used across provincial administrative regions.
Xiangcai Securities' research report pointed out that while several policies expand market boundaries, they significantly raise quality and compliance thresholds, driving the TCM industry from its past fragmented and inefficient competitive landscape towards refined value competition. The policies are pushing the TCM industry into a structural adjustment cycle of "entry and exit, survival of the fittest." The policy direction is becoming increasingly clear: open market boundaries, raise quality thresholds, and force industry upgrades through market-oriented means and scientific tools. Nationwide layout and supply chain management capabilities (for decoction piece enterprises), innovation, R&D, and evidence-based medicine evidence accumulation capabilities (for Chinese patent medicine enterprises), and whole-process quality management and traceability system construction capabilities (for the entire TCM industry) will become the three core capabilities for building competitive advantages.
Latest data shows that the CSI Traditional Chinese Medicine Index's dividend yield for the past year reached 3.12%. Based on the high-dividend characteristics of the index's constituent stocks, this fund can provide investors with relatively stable dividend income.
From a valuation perspective, the latest P/E ratio of the CSI Traditional Chinese Medicine Index tracked by the TCM ETF Huatai-PineBridge (560080) is only 23.05 times, at the 8.25% percentile since the index's inception, meaning the valuation is lower than 91.75% of the periods since the index's establishment.
The TCM sector combines the dual attributes of new domestic demand consumption and healthcare. Investors optimistic about the allocation value of TCM may consider focusing on the TCM ETF Huatai-PineBridge (560080), which leads the market in size. For over-the-counter, consider the Huatai-PineBridge CSI Traditional Chinese Medicine ETF Link Fund (A: 501011; C: 501012).
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
